The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus
Abstract
Type 2 diabetes mellitus is a severe disease with large economic consequences, which is significantly under-diagnosed and incompletely treated in the general population. Control of blood glucose levels is a key objective in treating diabetic patients, who are most often prescribed one or more oral hypoglycaemic agents in addition to diet and exercise modification as well as insulin. In spite of the availability of different classes of hypoglycaemic drugs, treatment regimens are often unable to achieve an intensive degree of glucose control known to most effectively reduce the incidence and severity of diabetic complications. Hepatic glucose output is elevated in type 2 diabetic patients and current evidence indicates that glycogenolysis (release of monomeric glucose from the glycogen polymer storage form) is an important contributor to the abnormally high production of glucose by the liver. Glycogen phosphorylase is the enzyme that catalyses this release and recent advances in new inhibitors of this structurally and kinetically well studied enzyme have enabled work which further delineate the pharmacological and physiological consequences of inhibiting glucose production by this pathway. Most notably, these agents lower glucose in diabetic animal models, both acutely and chronically, appear to affect both gluconeogenic and glycogenolytic pathways and demonstrate potential for a beneficial effect on cardiovascular risk factors. Cumulatively, this information has bolstered interest and promise in glycogen phosphorylase inhibitors (GPIs) as potential new hypoglycaemic agents for treatment of type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Amos, A. F., McCarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r · Cited by 1,882
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Asano, N., Nash, R. J., Molyneux, R. J., & Fleet, G. W. J. (2000) · Tetrahedron: Asymmetry · doi:10.1016/s0957-4166(00)00113-0 · Cited by 1,015
Carson, M. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891007240 · Cited by 808
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757 · cited 2×
“It is generally recognised that type 2 diabetics display elevated hepatic glucose production; in some studies this is due to proportionally greater gluconeogenic rates [34,36,37] but others [40,41] suggest that glycogenolysis is the elevated component.”
BackgroundEconomic Consequences of Diabetes Mellitus in the U.S. in 1997
American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.2.296 · Cited by 652
Cited by
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Molecular Mechanisms and Clinical Implications of Reversible Protein S -Glutathionylation
Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., & Shelton, M. D. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2089 · Cited by 523
Glucokinase and molecular aspects of liver glycogen metabolism
Agius, L. (2008) · Biochemical Journal · doi:10.1042/bj20080595 · Cited by 384
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Ayeleso, T., Matumba, M., & Mukwevho, E. (2017) · Molecules · doi:10.3390/molecules22111915 · Cited by 333
Allostery: an illustrated definition for the ‘second secret of life’
Fenton, A. W. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.05.009 · Cited by 320
Brown, A. M. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02421.x · Cited by 308
“The reason for this variability in glycogen content is unclear, but may be related to astrocytic density or local metabolic requirements of the tissue.”
BackgroundNew hepatic targets for glycaemic control in diabetes
Agius, L. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.001 · Cited by 155
Aiston, S., Coghlan, M. P., & Agius, L. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03648.x · Cited by 62
Effect of Ecdysterone on Glucose Metabolism in vitro
Chen, Q., Xia, Y., & Qiu, Z. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.06.031 · Cited by 51
MicroRNA Profiling in Aging Brain of PSEN1/PSEN2 Double Knockout Mice
Ham, S., Kim, T. K., Lee, S., Tang, Y.-P., & Im, H.-I. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0753-6 · Cited by 12
Metadata
- Authors
- Treadway, J. L., Mendys, P., & Hoover, D. J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2001-03
- Volume
- 10
- Issue
- 3
- Pages
- 439-454
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2154368316
- Cited by
- 260
- References
- 71
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.